Clinical Trials Browser

Phase 1/2 × Terminated × Tumor-Agnostic × Clear all

NCT04799054 2026-04-13

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT04009681 2025-12-15

HAMMER

Phase 1/2 Terminated

Neoplasm Metastasis, Neoplasms

NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Phase 1/2 Terminated

70 enrolled 14 charts

Neoplasm Metastasis

NCT04701281 2025-09-18

SYS-CAPLIOX

Phase 1/2 Terminated

Neoplasm Metastasis

NCT05220098 2025-08-29

First-in-Human Study of TAK-280 in Participants With Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT04418661 2025-05-29

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Phase 1/2 Terminated

65 enrolled 32 charts

Neoplasm Metastasis

NCT06290388 2024-12-04

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

Phase 1/2 Terminated

Neoplasms

NCT05525455 2024-11-21

TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)

Phase 1/2 Terminated

Neoplasms

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Phase 1/2 Terminated

4 enrolled 14 charts

Carcinoma, Squamous Cell

NCT03416335 2024-05-30

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Phase 1/2 Terminated

36 enrolled 17 charts

Neoplasms

NCT04319224 2024-05-30

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Phase 1/2 Terminated

4 enrolled 10 charts

Neoplasms

NCT04618393 2024-05-21

A Study of EMB-02 in Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis, Neoplasms

NCT05071183 2024-04-02

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Phase 1/2 Terminated

9 enrolled 17 charts

Neoplasm Metastasis

NCT01311713 2024-01-30

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Phase 1/2 Terminated

45 enrolled 16 charts

Neoplasms

NCT03722108 2023-10-16

REGIRI

Phase 1/2 Terminated

Adenocarcinoma

NCT03637764 2023-07-10

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Phase 1/2 Terminated

107 enrolled 30 charts

Neoplasms

NCT00886782 2023-04-28

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1/2 Terminated

11 enrolled 35 charts

Neoplasm Metastasis

NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

80 enrolled 33 charts

Neoplasms

NCT04800627 2022-12-27

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Phase 1/2 Terminated

2 enrolled 4 charts

Neoplasm Metastasis

NCT03363776 2020-12-19

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Phase 1/2 Terminated

10 enrolled 11 charts

Neoplasms

NCT02906670 2020-08-28

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

Phase 1/2 Terminated

32 enrolled 24 charts

Neoplasms

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Phase 1/2 Terminated

7 enrolled 6 charts

Neoplasms

NCT03138083 2020-06-11

OMO-1 in Solid Malignancies

Phase 1/2 Terminated

Neoplasms

NCT02224599 2020-04-24

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Phase 1/2 Terminated

3 enrolled 6 charts

Neoplasms

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis

NCT02434146 2019-12-09

Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy

Phase 1/2 Terminated

3 enrolled 5 charts

Neoplasms

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1/2 Terminated

15 enrolled 11 charts

Neoplasms

NCT01355302 2017-05-15

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Phase 1/2 Terminated

7 enrolled 8 charts

Neoplasms

NCT01848756 2017-02-09

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

Phase 1/2 Terminated

15 enrolled 10 charts

Neoplasms

NCT00201734 2016-09-23

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Phase 1/2 Terminated

57 enrolled 11 charts

Adenocarcinoma, Neoplasms, Neoplasms, Unknown Primary

NCT00924287 2015-10-28

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Phase 1/2 Terminated

1 enrolled 8 charts

Neoplasm Metastasis, Neoplasms

NCT00309023 2015-10-12

Study of BMS-663513 in Patients With Advanced Cancer

Phase 1/2 Terminated

Neoplasms

NCT01001221 2013-09-11

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Phase 1/2 Terminated

19 enrolled 55 charts

Neoplasms

NCT01242943 2011-11-22

Radioimmunotherapy With 131I-L19SIP in Patients With Cancer

Phase 1/2 Terminated

Neoplasms

NCT00557596 2009-12-01

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Phase 1/2 Terminated

Carcinoma

NCT00225550 2007-08-06

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT00104286 2006-11-03

Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors

Phase 1/2 Terminated

Neoplasms